Pure Global
NCT04943588

Treating Hepatitis C in Pakistan. Strategies to Avoid Resistance to Antiviral Drugs

Queen Mary University of London·ClinicalTrials.gov·diagnostic testNot yet recruiting
View on ClinicalTrials.gov →
Study focus
Disease/Condition
Hepatitis C, Chronic
Drug/Device/Intervention
HCV RNA (PCR)
Study type
Observational
Intervention type
diagnostic test
Sponsor & location
Primary sponsor
Queen Mary University of London
Timeline & enrollment
Phase
N/A
Start date
Jul 01, 2021
End date
Jan 01, 2023
Enrollment
25000 participants
Primary outcome

SVR,Incidence of new infections,Incidence of re-infection

Summary

We will determine how best to manage the hepatitis C virus (HCV) epidemic in Pakistan by
 measuring effectiveness of Pakistan-government sponsored current therapies, emergence of
 viral resistance, consequences of infection (chiefly liver cancer) and through developing
 models, based on incidence data, determine the proportion of people who need curative
 treatment to eliminate HCV, and assess whether targeting can optimise this.

ICD-10 classifications
Chronic viral hepatitis CAcute hepatitis CChronic hepatitis, unspecifiedChronic viral hepatitisChronic viral hepatitis, unspecified
Data source
Registry
ClinicalTrials.gov
Trial ID
NCT04943588
Type
Non-Device Trial
About this record

Access comprehensive clinical trial information for NCT04943588 through Pure Global AI's free database. This phase not specified trial is sponsored by Queen Mary University of London and is currently Not yet recruiting. The study focuses on Hepatitis C, Chronic. Target enrollment is 25000 participants.

This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.